Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Pancreatic Cancer Drugs Market From 2025 to 2029?

The market size of drugs targeting pancreatic cancer has seen a consistent expansion in the past few years. It is projected to increase from $3.97 billion in 2024 to $4.07 billion in 2025, recording a compound annual growth rate (CAGR) of 2.4%. The monumental growth during the historical period is owed to surging economic progress in emerging markets, a rise in the aging population, and a heightened incidence of pancreatic cancer.

Predictions indicate consistent expansion in the pancreatic cancer drugs market in the imminent years. It’s projected to amplify to “$4.7 billion in 2029 with a compound annual growth rate (CAGR) of 3.7%.” Factors contributing to this progression in the forecasting span include escalated cancer prevalence rates, an upward trend in healthcare spending, and enhanced governmental assistance. Key trends in the predicted timeframe encompass concentration on the creation of new medicinal solutions for pancreatic cancer, emphasis on innovative nanomedicine therapies, focus on escalating investments, strategic partnerships, and product enhancements.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2565&type=smp

What Elements Are Contributing To Growth In The Pancreatic Cancer Drugs Market?

The escalation in the frequency of pancreatic cancer is projected to stimulate the expansion of the pancreatic cancer drugs market. As the number of pancreatic cancer diagnoses soars, so does the need for medication, fuelling the expansion of the pancreatic cancer drugs market. The rise in cancer cases is primarily attributed to the growing elderly population and an uptick in the number of individuals afflicted with obesity. For example, the American Cancer Society predicts that approximately 64,050 individuals (33,130 men and 30,920 women) will be diagnosed with pancreatic cancer in 2023, with roughly 50,550 people (26,620 men and 23,930 women) expected to succumb to the disease.

The pancreatic cancer drugs market covered in this report is segmented –

1) By Type: Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs

2) By Drug Combination: Single, Double, Triplet, Quadruplet

3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users

Subsegments:

1) By Pancreatic Neuroendocrine Cancer Drugs: Somatostatin Analogs, Targeted Therapy Drugs, Chemotherapy Agents

2) By Pancreatic Exocrine Cancer Drugs: Chemotherapy Agents, Targeted Therapy Drugs, Immunotherapy Drugs

What Upcoming Trends Are Expected To Impact The Pancreatic Cancer Drugs Market Globally?

One of the recent developments in the pancreatic cancer drug market is the shift towards combination therapy instead of monotherapy. Key players in the market have recognized that the use of two or more drugs concurrently can heighten the drugs’ effectiveness, and consequently, improve the survival rate of patients diagnosed with pancreatic cancer. Among the companies that are investing in combination therapy, Rafael Pharmaceuticals has launched the Pivotal Phase 3 Trial (AVENGER 500) for CPI-613 (delimitate) used together with Modified FOLFIRINOX intended as the primary treatment for patients with metastatic pancreatic cancer. Apexigen, Inc., a company in the clinical-stage biopharmaceutical sector, has disclosed new clinical data on APX005M used in combination therapy of patients with metastatic pancreatic cancer.

Who Are The Key Contributors To Growth In The Pancreatic Cancer Drugs Market?

Major companies operating in the pancreatic cancer drugs market include Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Novartis AG, Abbvie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries, Amgen Incorporation, Eli Lilly And Company, Beigene, Chi-Med, Cstone Pharmaceuticals, Voxtur Bio Ltd, Shantu Pharma, Krushi Mitra, Kremedine Health Private Limited, Arlak Biotech, Healthkind Labs Pvt. Ltd, Swisschem Healthcare Pvt Ltd, Apikos Pharma, GlaxoSmithKline Plc, Veropharm, Biocad, Celon Pharma, Celgene Corporation, Johnson & Johnson, Bayer AG, Tabuk Pharmaceuticals, Julphar Life Sciences, Eurolab, Sanofi, Aspen, Zahraa Oncology

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Which Region Is Projected To Lead The Pancreatic Cancer Drugs Market By 2025?

North America was the largest region in the pancreatic cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global pancreatic cancer drugs market share during the forecast period. The regions covered in the pancreatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2565&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model